General
Preferred name
nateglinide
Synonyms
A4166 ()
Senaglinide ()
Starlix,A-4166,SDZ DJN 608 ()
Trazec ()
AY-4166 ()
DJN-608 ()
D-nateglinide ()
AY4166 ()
DJN 608 ()
SDZ DJN 608 ()
A-4166 ()
NSC-758695 ()
SDZ-DJN-608 ()
Nateglinida ()
Starlix ()
Starsis ()
Nateglinide ()
Nateglinide-d5 ()
P&D ID
PD003079
CAS
105816-04-4
1227666-13-8
Tags
available
drug
Approved by
FDA
First approval
2000
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Drug indication
diabetes mellitus
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION A sulfonylurea receptor 1, Kir6.2 blocker, but belonging to the metiglinides drug family. Note that the PubChem CID listed here is a slightly different isomer to the ChEMBL ligand and the INN structure. (GtoPdb)
DESCRIPTION Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic ¦Â-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].
PRICE 29
DESCRIPTION Potent P2X7 antagonist (Tocris Bioactive Compound Library)
DESCRIPTION Kir6 (KATP) blocker; displays high affinity for SUR1/Kir6.2 channels (Tocriscreen Plus)
DESCRIPTION Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus. It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. (Enamine Bioactive Compounds)
DESCRIPTION Nateglinide (Senaglinide) is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Nateglinide has been linked to rare instances of clinically apparent acute liver injury. (TargetMol Bioactive Compound Library)
Compound Sets
24
Cayman Chemical Bioactives
23320
30151
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL783
ChEMBL Drugs
CHEMBL783
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00731
DrugBank Approved Drugs
DB00731
DrugCentral
1886
DrugCentral Approved Drugs
1886
Enamine Bioactive Compounds
EBC-11228
Enamine BioReference Compounds
Guide to Pharmacology
6833
MedChem Express Bioactive Compound Library
HY-B0422
NCATS Inxight Approved Drugs
41X3PWK4O2
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Nateglinide(Starlix)
TargetMol Bioactive Compound Library
T1674
Tocris Bioactive Compound Library
4231
Tocriscreen Plus
4231
Withdrawn 2.0
EMA28
External IDs
48
Properties
(calculated by RDKit )
Molecular Weight
317.2
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
2
Rotatable Bonds
6
Ring Count
2
Aromatic Ring Count
1
cLogP
3.26
TPSA
66.4
Fraction CSP3
0.58
Chiral centers
1.0
Largest ring
6.0
QED
0.85
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Ion Channels
MOA
sulfonylurea receptor agonist
Potassium Channel inhibitor
PPAR agonist
Blocker
K(ir) 6.2/SUR1 Blockers
Insulin Secretagogues
insulin secretagogue
Target
Sulfonylurea receptor 1, Kir6.2
Dipeptidyl Peptidase
Potassium Channel
PPARγ
PPAR¦Ã
ABCC8, KCNJ10, KCNJ11, PPARG
Primary Target
Inward Rectifier Potassium (Kir) Channels
Member status
member
Indication
diabetes mellitus
ATC
A10BX03
Pathway
DNA Damage/DNA Repair
Membrane Transporter/Ion Channel
Metabolism
Proteases/Proteasome
Ubiquitination
Metabolic Enzyme/Protease
Source data